Conclusion: Shared decision making between clinicians and patients is appropriate for decisions about extended adjuvant endocrine treatment, including discussions about the absolute benefits in the reduction of breast cancer recurrence, the prevention of second breast cancers, and the impact of adverse effects of treatment. Additional information can be found at www.asco.org/breast-cancer-guidelines .
Aromatase Inhibitor side effects
Across 26 first-hand reports, people mentioned a side effect 8 times (about 31 per 100 reports). The most common: nasty sides, dry joints, crashed estrogen. User reports show what people notice — they can't tell you whether Aromatase Inhibitor is safe for you.
Reported side effects
nasty sides1
dry joints1
crashed estrogen1
estrogen crash1
lipid profile1
eye issues1
joint issues1
achy joints1
In their own words
“aromatase inhibitors (even at ultra low doses) crashed my estrogen”
Is Aromatase Inhibitor safe? What the research covers
AResearch: Strong125 meta-analyses · 492 randomized trials on PubMed
J Clin Oncol · 2019
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused UpdateCancer Treat Rev · 2022
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortalityConclusion: These benefits and risks inform treatment decisions for individuals and recommendations for groups of women.